NUAK Inhibitors as Therapeutics for Cancer and Fibrosis

BACKGROUND

The Hippo signaling pathway is a key regulator of cell proliferation and cell death. High cell density and stress activate the pathway to stop cell proliferation and induce apoptosis.  It has consequently been linked to diseases such as cancer and fibrosis.  At the molecular level, the Hippo kinase cassette controls the activity of the transcriptional regulators, YAP and TAZ, through phosphorylation events (Figure 1a).  Phosphorylation of YAP and TAZ by a kinase of the Hippo pathway, LATS, results in cytoplasmic localization where these molecules cannot exert their function.  However, unphosphorylated YAP and TAZ localize to the nucleus where they can interact with transcription factors (e.g. TEAD) to turn on gene transcription and promote pro-oncogenic, pro-fibrotic outcomes.  This implies that molecules that promote TAP and TAZ phosphorylation can act as therapeutics for cancer and fibrosis.

 

TECHNOLOGY

Researchers at the University of Toronto have identified a kinase, NUAK2 (& the closely related NUAK1), that promotes YAP and TAZ oncogenic and fibrotic activity. NUAK2 acts in a positive feed forward loop where it prevents the phosphorylation of YAP and TAZ by a Hippo kinase (Figure 1b). They have shown that gene knockdown or small molecule inhibition of NUAKs restores pathway activity and inhibits both tumorigenic and fibrotic properties in cells and in mice models. In collaboration with the OICR Drug Discovery Program, the group has undertaken efforts to identify novel potent small molecule inhibitors of NUAKs. Numerous experimental tools, including in-vitro and cell-based assays (in low & high-throughput formats) have been developed to measure Hippo pathway activity confirming on-target effects. Through these efforts, the team has generated novel inhibitors (currently in the lead optimization stage) of the NUAKs that demonstrate potent activity in both cell-based assays and animal studies.

Figure 1.  Hippo signalling pathway. a.  Extracellular cues turn on the Hippo pathway which results in phosphorylation and cytoplasmic retention of YAP/TAZ; unphosphorylated TAP/TAZ localise to the nucleus where the exert pro-oncogenic, pro-fibrotic functions.  b. Negative regulation of the Hippo pathway by NUAK2 promotes oncogenesis and fibrosis.

 

COMPETITIVE ADVANTAGE

  • Two classes of novel inhibitor compounds for NUAKs: IC50 in the nM range
  • NUAK1 and NUAK2 are elevated in broad disease indications based on Caner and Fibrosis
  • Drug screening capabilities: Identification of NUAK2 as a negative regulator of Hippo provides a new opportunity to develop kinase inhibitors that would counteract the oncogenic functions of YAP/TAZ.

 

APPLICATIONS

  • Cancer therapeutic
    • Multiple solid cancers: breast, colon, bladder, HNSCC, others
  • Fibrosis therapeutic
    • Kidney, lung, liver, pancreas, others

 

INTELLECTUAL PROPERTY STATUS

  • Provisionals filed (Jan 2021) for two classes of compounds

 

PROJECT STATUS

Proof-of-principal studies have been conducted in cell lines and mouse models of cancer and fibrosis.  Two classes of NUAK inhibitors have been developed.

Figure 2.  A small molecule compound (NUAK inhibitor) inhibits tumor growth in a late stage breast cancer model (orthotopic MDA-MB-231) in immunocompromised (NSG) mice leading to increased survival.

 

ID:

P2143

Keywords:

Therapeutics

Related Resources

VPRI Contact

Ian Stewart

Innovations & Entrepreneurship Manager
Innovations & Partnerships Office (IPO)
(416) 946-7734